We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-16.51%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$3.2B
AUM Growth
+$184M
(+6.1%)
Cap. Flow
+$679M
Cap. Flow
% of AUM
21.24%
Top 10 Holdings %
Top 10 Hldgs %
52.91%
Holding
52
New
11
Increased
20
Reduced
7
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$126M |
| 2 |
Danaher
DHR
|
+$126M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$124M |
| 4 |
Intuitive Surgical
ISRG
|
+$105M |
| 5 |
IQVIA
IQV
|
+$93.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$218M |
| 2 |
Merck
MRK
|
+$132M |
| 3 |
HCA Healthcare
HCA
|
+$118M |
| 4 |
AGN
Allergan plc
AGN
|
+$117M |
| 5 |
Labcorp
LH
|
+$106M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$784B
| $350M | 10.94% |
+1,400,000
| New | +$378M |
|
|
2
Intuitive Surgical
ISRG
$126B
| $186M | 5.81% |
1,163,760
+622,380
| +115% | +$105M |
|
|
3
DexCom
DXCM
$28.8B
| $176M | 5.5% |
5,875,008
+3,976,288
| +209% | +$126M |
|
4
Regeneron Pharmaceuticals
REGN
$76B
| $165M | 5.15% |
440,968
+40,968
| +10% | +$15M |
|
|
5
Danaher
DHR
$138B
| $155M | 4.85% |
1,696,230
+1,384,676
| +444% | +$126M |
|
6
CVS Health
CVS
$134B
| $153M | 4.77% |
2,328,560
+1,048,800
| +82% | +$78.3M |
|
7
LivaNova
LIVN
$4.45B
| $139M | 4.34% |
1,517,780
+822,670
| +118% | +$88.3M |
|
8
Medtronic
MDT
$110B
| $134M | 4.19% |
1,472,790
-217,060
| -13% | -$20.3M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $125M | 3.9% |
1,947,640
+1,011,472
| +108% | +$74.7M |
|
10
Cigna
CI
$76.1B
| $111M | 3.47% |
584,390
-15,610
| -3% | -$3.26M |
|
11
Haemonetics
HAE
$3.85B
| $110M | 3.44% |
1,100,140
+800,901
| +268% | +$84.1M |
|
|
WCG
12
DELISTED
Wellcare Health Plans, Inc.
WCG
| $109M | 3.41% |
+462,370
| New | +$124M |
|
13
Pacira BioSciences
PCRX
$1.06B
| $107M | 3.36% |
2,498,128
+552,588
| +28% | +$25.8M |
|
14
Stryker
SYK
$133B
| $93M | 2.91% |
593,623
-281,377
| -32% | -$47.1M |
|
|
15
IQVIA
IQV
$39.1B
| $89.5M | 2.8% |
+770,550
| New | +$93.3M |
|
16
UnitedHealth
UNH
$383B
| $84M | 2.63% |
337,280
-11,240
| -3% | -$2.97M |
|
17
Madrigal Pharmaceuticals
MDGL
$11.4B
| $77.7M | 2.43% |
688,890
+426,030
| +162% | +$65.9M |
|
|
18
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
| $71.2M | 2.23% |
+285,000
| New | +$76.9M |
|
|
XENT
19
DELISTED
Intersect ENT, Inc
XENT
| $70.2M | 2.19% |
2,490,110
+540,110
| +28% | +$15.8M |
|
20
Encompass Health
EHC
$11B
| $68.2M | 2.13% |
+1,390,141
| New | +$79.1M |
|
21
Boston Scientific
BSX
$68.4B
| $63.4M | 1.98% |
1,794,610
+391,660
| +28% | +$14.2M |
|
|
RDUS
22
DELISTED
Radius Health, Inc.
RDUS
| $61.4M | 1.92% |
3,723,949
+139,369
| +4% | +$2.35M |
|
|
MDCO
23
DELISTED
Medicines Co
MDCO
| $55M | 1.72% |
2,871,283
+2,189,083
| +321% | +$50.9M |
|
24
Neurocrine Biosciences
NBIX
$18.7B
| $54.9M | 1.72% |
768,630
+358,274
| +87% | +$34.3M |
|
|
CELG
25
CALL
DELISTED
Celgene Corp
CELG
| $48.1M | 1.5% |
+750,000
| New | +$55.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2018 Portfolio in Review
As of Q4 2018, HealthCor Management held 52 positions worth $3.2B, up 6.1% from $3.02B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
HealthCor Management deployed $679M of net new capital in Q4 2018, opening 11 new positions and adding to 20 existing holdings. Its largest new stake was Wellcare Health Plans, Inc.: 462,370 shares worth $109M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 88% a quarter earlier.
On the sell side, the largest reduction was Zimmer Biomet, an estimated $218M trimmed.
- HealthCor Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 462,370 shares worth $109M.
- HealthCor Management added most to DexCom in Q4 2018, an estimated $126M increase.
- HealthCor Management's biggest Q4 2018 reduction was Zimmer Biomet, cutting an estimated $218M.
- HealthCor Management fully exited HCA Healthcare in Q4 2018, selling an estimated $118M.
- HealthCor Management's ten largest holdings make up 53% of its $3.2B portfolio in Q4 2018.
- HealthCor Management opened 11 new positions and closed 12 in Q4 2018.
- HealthCor Management's portfolio value rose 6.1% quarter-over-quarter to $3.2B.
Based on HealthCor Management's 13F filing for Q4 2018, filed 14 Feb 2019.